GWPH News and Press, GW Pharmaceuticals Plc From 09/23/20

GW Pharmaceuticals (GWPH) announces that the Australian Therapeutic Goods Administration ((TGA)) has approved EPIDYOLEX (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut syndrome ((LGS)) or Dravet syndrome ((DS)) in patients two years of age and older.LGS/DS...

LONDON, Sept. 23, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the Au...

Though cannabis stocks are expected to remain volatile, you can bet on niche and ancillary players to generate market-beating returns, such as Innovative Industrial Properties (IIPR), GW Pharmaceuticals (GWPH), and Scotts Miracle-Gro (SMG). Marijuana stocks have taken investors on a wild...

Advancing science as a biotechnology company rarely goes exactly as planned, and Zynerba Pharmaceuticals ( ZYNE ) is no exception. When they reported data from their pivotal CONNECT-FX trial, the market's reaction was harsh, with the stock dropping 50%. CONNECT-FX studied Zynerba's lead compou...

GW Pharmaceuticals plc (GWPH) Morgan Stanley 18th Annual Global Healthcare Conference September 15, 2020 4:15 PM ET Company Participants Justin Gover - Chief Executive Officer Darren Cline - Chief Commercial Officer Conference Call Participants David Lebowitz - Morgan Stanley...

CARLSBAD, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, will present r...

- Results from post-hoc analysis of phase 3 clinical study show nabiximols was well-tolerated and provided continued reductions in spasticity for individuals who remained on therapy - Analysis of two placebo-controlled randomized trials shows nabiximols had no notable negative effects...

Oversupply, pricing headwinds, inventory writedowns, and retail store closures due to COVID-19 containment measures -- these things and more have meant a tough year for the legal marijuana market worldwide. Since the beginning of January, the Horizons Marijuana Life Sciences ETF (TSX: HMM...

LONDON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines today announced the appointment of David Gryska to the Board of Directors. Mr. Gryska will also serve a...

If you want to invest in cannabis companies that are safe, long-term bets, you might be hard-pressed to find a few standouts. If one thing's for certain, though, it's that investors should at least consider picking stocks that aren't dependent on recreational marijuana, where future growth is st...